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Abstract: Acute morphine administration decreases cardiac responses to ischaemic injury. This project has determined whether
induction of morphine dependence in rats by gradually increasing morphine doses for 21 days induces structural and functional
changes in the cardiovascular system because of mineralocorticoid receptor activation, as morphine increases plasma corticoste-
rone concentrations. Morphine-dependent rats showed ventricular hypertrophy, increased collagen deposition in the left ventricle
together with an increased ventricular stiffness and increased plasma malondialdehyde concentrations without changes in systolic
blood pressure or thoracic aortic responsiveness. These parameters were attenuated or normalised in morphine-dependent rats
treated with spironolactone (50 mg/kg/day) from days 14–21. These results suggest that morphine dependence induces ventricular
remodelling and increased oxidative stress that can be prevented by the mineralocorticoid receptor antagonist, spironolactone.
The major therapeutic beneﬁt of opiates such as morphine has
been pain relief, although these compounds also provide pro-
tection from injury for the cardiovascular system. When
administered 10 min. before cardiac ischaemia, morphine
(0.3 mg/kg) induced pre-conditioning of the heart to reduce
infarct size after coronary artery ligation [1]. Morphine also
induced a late onset pre-conditioning occurring after more than
24 hr in part by activation of nuclear factor-jB [2]. Morphine
decreased infarct size through activation of d-opioid receptors
when applied in a post-conditioning protocol after ischaemia,
probably by targeting the mitochondrial permeability transition
pore [3]. Protection after ischaemia-reperfusion injury by mor-
phine is not limited to the heart: morphine-dependent rats
showed decreased tissue injury after renal artery clamping [4].
Further, morphine protected the heart against injury by the
anti-cancer drug, doxorubicin [5].
In contrast, the direct cardiovascular effects of morphine
include changes in blood pressure. Intermittent injections of
morphine (2.5–20 mg/kg sc over 13 days) and spontaneous
withdrawal from these injections were associated with pro-
nounced and prolonged increases in mean arterial pressure [6].
Continuous subcutaneous administration of morphine (10–
30 mg/kg/day for 7 days) increased blood pressure on the ﬁrst
day but decreased blood pressure on subsequent days [7]. A
single dose of morphine (3 mg/kg sc) produced hypotension
in Spontaneously Hypertensive Rats compared to normoten-
sive Wistar-Kyoto rats [8]. In healthy male volunteers with
experimental pain, two doses of morphine as an intravenous
bolus caused a transient, initial and dose-dependent increase in
mean arterial pressure and oxygen consumption [9].
This study has characterised the changes in cardiac and vas-
cular structure and function in morphine-dependent rats. Fur-
ther, we have investigated whether treatment with the
mineralocorticoid antagonist, spironolactone, improves the car-
diovascular changes by attenuation of the oxidative stress and
cardiac remodelling. Spironolactone was chosen because it
decreased cardiac remodelling in DOCA-salt hypertensive rats
[10]. Further, morphine administration in rats activated the
hypothalamus-pituitary-adrenal axis to increase serum concen-
trations of corticosterone, an agonist at both mineralocorticoid
and glucocorticoid receptors [11]. Corticosterone concentra-
tions were also increased during morphine withdrawal [12]
and treatment with spironolactone overcame the memory
impairment induced by morphine withdrawal [13], suggesting
that the increased corticosterone concentrations in morphine-
dependent rats may initiate cardiovascular responses in mor-
phine-dependent rats through mineralocorticoid receptors.
Materials and Methods
Rats. Male Wistar rats (8–10 weeks old, 318 ± 6 g, n = 45) were
obtained from the Central Animal Breeding House of The University of
Queensland. All experimental protocols were approved by the Animal
Experimentation Ethics Committee of The University of Queensland
under the guidelines of the National Medical and Health Research
Council, Australia. Rats were given ad libitum access to food and water
and were housed in 12 hr light: dark conditions. Five experimental
groups, each of nine rats, were used for this study: (i) control, (ii)
spironolactone-treated control rats (50 mg/kg/day sc for 7 days after
day 14), (iii) morphine-dependent, (iv) morphine-dependent rats
administered naloxone (1 mg/kg sc) once only on day 21 and (v)
morphine-dependent rats treated with spironolactone (50 mg/kg sc)
from day 14 for the last 7 days. Rats were made morphine‐dependent
by increasing the morphine concentration in the drinking water every
48 hr from 0.1 to 0.2, to 0.3 and ﬁnally to 0.4 mg/ml for a total of
21 days [14]. Cardiovascular assessments or histology were performed
on day 21 with no further treatment (groups 1, 2, 3 and 5); naloxone-
treated rats (group 4) were observed for adverse effects for 20 min.
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after injection. After naloxone administration, the following behavioural
parameters were assessed: diarrhoea, teeth chattering, tremor, ptosis,
rhinorrhoea, piloerection, lacrimation and jumping.
Assessment of physiological parameters. Body weight, food and water
intakes were measured daily. Systolic blood pressure was measured
after 0, 2 and 3 weeks under light sedation with i.p. injection of Zole-
til (tiletamine 15 mg/kg, zolazepam 15 mg/kg), using an MLT1010
Piezo-Electric Pulse Transducer (ADInstruments, Sydney, Australia)
and inﬂatable tail-cuff connected to a MLT844 Physiological Pressure
Transducer (ADInstruments) and PowerLab data acquisition unit
(ADInstruments). Rats were killed with an injection of pentobarbitone
sodium (100 mg/kg i.p.). Blood was taken from the abdominal vena
cava and centrifuged, and the plasma was frozen. Plasma malondialde-
hyde concentrations, as a measure of oxidative stress, were determined
by HPLC [15].
Isolated heart preparation. The left ventricular function of the rats in
all treatment groups was assessed using the Langendorff heart prepa-
ration. Terminal anaesthesia was induced via i.p. injection of pento-
barbitone sodium (100 mg/kg). Once anaesthesia was achieved,
heparin (1000 IU) was injected into the right femoral vein. Isovolu-
metric ventricular function was measured by inserting a latex balloon
catheter into the left ventricle connected to a Capto SP844 MLT844
physiological pressure transducer and Chart software on a Maclab sys-
tem. All left ventricular end-diastolic pressure values were measured
by pacing the heart at 250 beats per min. using an electrical stimula-
tor. End-diastolic pressures were obtained starting from 0 mmHg up
to 30 mmHg. The right and left ventricles were separated and
weighed. Diastolic stiffness constant (j, dimensionless) as the slope
of the linear relationship between E and r was calculated as in previ-
ous studies [10,16] by calculating stress (r, dyne/cm2) and tangent
elastic modulus (E, dyne/cm2) for the midwall at the equator of the
left ventricle assuming spherical geometry of the ventricle and consid-
ering the midwall equatorial region as representative of the remaining
myocardium:
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Where V is chamber volume (ml), W is the left ventricular wall vol-
ume (0.943 ml/g ventricular weight), and P is the end-diastolic pres-
sure (dyne/cm3 = 1.5 9 104 mmHg).
Organ bath studies. Thoracic aortic rings (4 mm in length) were
suspended in an organ bath chamber with a resting tension of 10 mN.
Cumulative concentration–response (contraction) curves were mea-
sured for noradrenaline; concentration–response (relaxation) curves
were measured for acetylcholine and sodium nitroprusside in the pres-
ence of a stable contraction to noradrenaline (3 9 106M) producing
a submaximal response in control thoracic aortic rings [16].
Organ weights. After euthanasia, the heart, liver, kidneys and spleen
were removed and blotted dry for weighing. Organ weights were
normalised relative to the body-weight at the time of their removal (in
milligram per gram).
Confocal microscopy. Collagen distribution was measured in the left
ventricle after staining with picrosirius red and analysed by laser con-
focal microscopy. Tissues were initially ﬁxed for 3 days in Telly’s ﬁx-
ative (100 ml 70% ethanol, 5 ml glacial acetic acid and 10 ml 40%
formaldehyde) and then transferred into modiﬁed Bouin’s ﬂuid (85 ml
saturated picric acid, 5 ml glacial acetic acid and 10 ml 40% formal-
dehyde) for 2 days. The samples were then dehydrated and embedded
in parafﬁn wax. Thick sections (15 lm) were cut, stained, and image
analysis under the laser scanning microscope was performed as previ-
ously described [16]. Thin sections (10 lm) of left ventricle were cut
and stained with haematoxylin and eosin for determination of inﬂam-
matory cell inﬁltration.
Statistical analysis. All data sets were represented as group
mean ± standard error of mean (S.E.M.). Comparisons or ﬁndings
between groups were made via statistical analysis of data sets using
either an unpaired t-test or one-way/two-way analysis of variance fol-
lowed by the Duncan test to determine differences between treatment
groups. A p-value of <0.05 was considered as statistically signiﬁcant.
Drugs. Morphine, spironolactone, heparin, noradrenaline, acetylcholine
and sodium nitroprusside were purchased from Sigma Chemical Com-
pany (St. Louis, MO, USA). Morphine, noradrenaline, acetylcholine
and sodium nitroprusside were dissolved in distilled water. Spironolac-
tone was dissolved in 80% dimethylformamide. Naloxone was
obtained from the School of Veterinary Science of The University of
Queensland.
Results
Rats received a total of 194.4 ± 10.1 mg morphine in the
21-day protocol; the average intake on days 18–21 was 46.8 ±
2.6 mg in rats with an average body-weight of 383 ± 13 g.
On the last 3 days, the average morphine dose was 31.2 ±
3.0 mg/kg/day on day 18, 29.7 ± 2.0 mg/kg/day on day 19
and 32.4 ± 2.8 mg/kg/day on day 20 before terminal experi-
ments on day 21. All nine animals showed typical withdrawal
signs after naloxone administration (group 4) including lacri-
mation, piloerection, teeth chattering and tremor. Further, six
of these nine animals exhibited diarrhoea and ptosis but only
two animals exhibited rhinorrhoea and jumping.
Morphine administration in these rats did not change the rate
of body weight gain but addition of spironolactone selectively
decreased body weight in morphine-dependent rats compared
to other experimental groups (ﬁg. 1). Further, morphine-
dependent rats displayed decreased food and water intakes
compared to other experimental groups (ﬁgs 2 and 3). Systolic
blood pressure was unchanged after 21 days of treatment with
morphine alone, or with 7 days of spironolactone treatment
(table 1). However, naloxone administration acutely increased
systolic blood pressure (131 ± 4 mmHg) on day 21. Morphine
administration led to increased left ventricular wet weight
together with increased interstitial collagen deposition (ﬁg. 4,
table 1). Isolated Langendorff heart preparations showed
increased diastolic stiffness in morphine-dependent rats without
any changes in contractility or relaxation of the heart (table 1).
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Plasma malondialdehyde concentrations were increased by
morphine dependence (table 1). Further, morphine dependence
decreased contractile responses and increased potency to nor-
adrenaline and decreased relaxant responses to sodium nitro-
prusside in isolated thoracic aortic rings (ﬁg. 5).
Treatment with spironolactone (50 mg/kg s.c. for ﬁnal
7 days) attenuated the increased left ventricular wet weight,
interstitial collagen deposition, diastolic stiffness and plasma
malondialdehyde concentrations in morphine-dependent rats
(table 1). In the isolated thoracic aortic rings, spironolactone
treatment increased noradrenaline and acetylcholine potency
but decreased relaxant responses to sodium nitroprusside
(ﬁg. 5).
Discussion
Morphine dependency and withdrawal can both increase corti-
costerone concentrations [11,12] that could activate mineralo-
corticoid receptors in the heart thereby altering the normal
functioning of the cardiovascular system. This study suggests
that antagonism of aldosterone receptors by spironolactone
reverses the morphine-induced cardiac remodelling in mor-
phine dependency in rats, without changing systolic blood
pressure.
The unchanged systolic blood pressure after 21 days of
increasing oral morphine can be compared with increases of
25–40% in mean arterial pressure that returned to normal
within 6–8 hr with injected morphine [6] and increased sys-
tolic and diastolic blood pressure on the ﬁrst day of morphine
treatment by continuous subcutaneous administration but
decreased systolic and diastolic blood pressure thereafter [7].
Similar to the results in our study, antagonist-initiated
morphine withdrawal increased blood pressure in rats [17] and
in human beings [18]. Cardiac hypertrophy and ﬁbrosis
observed in morphine-dependent rats are characteristic of car-
diac remodelling [19]. Excessive collagen deposition impedes
the contractile function of the muscle ﬁbres of the heart, and
thus can result in an increased diastolic stiffness [20].
Acute and chronic morphine treatment in rats resulted in
persistent elevation of basal corticosterone secretion [11].
Plasma corticosterone concentrations were not measured in
this study because the cardiovascular changes in this study are
likely to be as a result of changes in mineralocorticoid recep-
tor density or activation in the heart and vessels, as these
responses were blocked by the receptor antagonist, spironolac-
tone. Changes in corticosterone concentrations have been
associated with memory loss during morphine withdrawal [12]
and with improvement in the memory index after spironolac-
tone treatment [13]. Corticosterone exerts its actions via min-
eralocorticoid and glucocorticoid receptors. Mineralocorticoid
receptors with a high afﬁnity (KD approximately 0.5–2 nM)
for cortisol, corticosterone and aldosterone [21] have been
identiﬁed in the myocardium and vascular wall as in other
organs [22]. Aldosterone receptor antagonism with spironolac-
tone decreased ventricular hypertrophy and ﬁbrosis in experi-
mental models of myocardial damage [10,23] and in patients
with systolic left ventricular dysfunction [24]. Aldosterone
receptor antagonism improved noradrenaline uptake into the
myocardium, decreased circulating noradrenaline concentra-
tions, decreased QT dispersion and ventricular arrhythmias,
and improved both baroreceptor function and heart rate vari-
ability [25]. Aldosterone receptor antagonism may decrease
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Fig. 1. Body weight for control (□, n = 6), control + spironolactone
(○, n = 6), morphine-dependent (■, n = 8) and morphine-dependent +
spironolactone (●, n = 6) rats. *p < 0.05 versus control, #p < 0.05
versus morphine-dependent group.
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Fig. 2. The daily food consumption (g/day) for control (□, n = 6),
control + spironolactone (○, n = 6), morphine-dependent (■, n = 8)
and morphine-dependent + spironolactone (●, n = 6) rats. *p < 0.05
versus control, #p < 0.05 versus dependent group.
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Fig. 3. The daily solution consumption (ml/day) for control (□, n = 6),
control + spironolactone (○, n = 6), morphine-dependent (■, n = 8)
and morphine-dependent + spironolactone (●, n = 6) rats. *p < 0.05
versus control, #p < 0.05 versus dependent group.
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reactive oxygen species (ROS) production and increase the
availability of nitric oxide [26]. Spironolactone treatment
caused an increase in noradrenaline potency possibly due to
electrolyte changes such as hyperkalaemia and hyponatraemia
induced by the drug. Spironolactone increased vascular relaxa-
tion response to acetylcholine that could also be due to elec-
trolyte changes.
Spironolactone has structural similarities to progesterone
and oestradiol; thus, it is associated with progestogenic, oes-
trogenic and androgenic adverse effects. As eplerenone has
Table 1.
Physiological parameters.
Parameters Control
Control +
spironolactone Morphine-dependent
Morphine-dependent +
spironolactone
LV + septum (mg/g body wt) 1.92 ± 0.07 (n = 6) 1.60 ± 0.04 (n = 6) 2.11 ± 0.08 (n = 8)* 1.83 ± 0.06 (n = 6)#
RV (mg/g body wt) 0.45 ± 0.02 (n = 6) 0.37 ± 0.01 (n = 6) 0.44 ± 0.02 (n = 8) 0.39 ± 0.01 (n = 6)
Kidneys (mg/g body wt) 6.33 ± 0.09 (n = 6) 5.75 ± 0.48 (n = 6) 6.91 ± 0.23 (n = 8) 7.17 ± 0.20 (n = 6)
Liver (mg/g body wt) 36.8 ± 1.7 (n = 6) 36.2 ± 1.2 (n = 6) 34.3 ± 0.9 (n = 8) 34.4 ± 1.6 (n = 6)
Blood pressure (mmHg) week 0 115 ± 3 (n = 8) 113 ± 3 (n = 6) 114 ± 3 (n = 9) 113 ± 2 (n = 6)
Blood pressure (mmHg) week 3 121 ± 2 (n = 8) 121 ± 7 (n = 6) 121 ± 5 (n = 7) 117 ± 3 (n = 6)
LV interstitial collagen (%) 1.0 ± 0.2 (n = 6) 1.8 ± 0.4 (n = 4) 3.0 ± 0.5 (n = 7)* 0.9 ± 0.1 (n = 6)#
Diastolic stiffness constant (j) 18.1 ± 1.8 (n = 6) 21.0 ± 0.8 (n = 6) 24.0 ± 0.8 (n = 6)* 20.5 ± 1.2 (n = 6)#
Maximal rate of contraction (dP/dt; mmHg/s) 1320 ± 70 (n = 6) 1420 ± 90 (n = 6) 1400 ± 60 (n = 6) 1250 ± 60 (n = 6)
Maximal rate of relaxation (dP/dt, mmHg/s) 1180 ± 30 (n = 6) 1280 ± 60 (n = 6) 1280 ± 30 (n = 6) 1180 ± 40 (n = 6)
Plasma malondialdehyde concentration (lM) 25.3 ± 1.1 (n = 9) 22.7 ± 0.7 (n = 9) 33.9 ± 4.0 (n = 9)* 24.3 ± 0.9 (n = 9)#
Aortic wall thickness (lm) 156 ± 6 (n = 6) 140 ± 10 (n = 7) 171 ± 10 (n = 6) 169 ± 9 (n = 7)
Values are group mean ± S.E.M.; number of experiments in parentheses. LV, left ventricle; RV, right ventricle.
*p < 0.05 versus control. #p < 0.05 versus morphine-dependent group.
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Fig. 4. Representative images of picrosirius red-stained left ventricular interstitial collagen (magniﬁcation,940) in control (A), morphine-dependent
(B), control + spironolactone (C), and morphine-dependent + spironolactone (D) rats.
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similar effects on cardiac function to spironolactone [27],
despite minimal binding to oestrogen, androgen or progesto-
gen receptors, it is assumed that the major cardiovascular
response to spironolactone is through mineralocorticoid recep-
tors. Eplerenone responses on morphine effects have not been
evaluated.
These results indicate that the cardiac remodelling and oxi-
dative stress in morphine-dependent rats can be prevented by
treatment with the mineralocorticoid receptor antagonist, spir-
onolactone, suggesting that these receptors play an important
role in mediating the cardiovascular changes in morphine-
dependent rats.
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